Concepedia

Author

Anna Berkenblit

Dana-Farber Cancer Institute

Also Known As

A Berkenblit, A. Berkenblit, Anna Berkenblit

68

Publications

4.9K

Citations

29

H-Index

41

Concepts

All Affiliations

Dana-Farber Cancer InstituteBeth Israel Deaconess Medical CenterImmunoGen (United States)Memorial Sloan Kettering Cancer CenterUniversity of Oklahoma Health Sciences Center
AB

About

Anna Berkenblit is an author at Dana-Farber Cancer Institute specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

15

20

1.3K

2

Health Sciences

4

4

167

3

Immunology

2

2

75

4

Nephrology

2

2

48

5

Gastroenterology

1

1

105

Anna Berkenblit

×

34

Publications

4.3K

Citations

25

H-Index

YearCitations

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Raoul Herbrecht, Jorge Romaguera, Gregor Verhoef,

Journal of Clinical Oncology

2009

639

Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

Robert J. Motzer, Dmitry Nosov, Timothy Eisen,

Journal of Clinical Oncology

2013

438

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

Kathleen N. Moore, Antoine Angelergues, Gottfried E. Konecny,

New England Journal of Medicine

2023

316

Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer

Ursula A. Matulonis, Suzanne Berlin, Percy Ivy,

Journal of Clinical Oncology

2009

300

Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Antonio C. Wolff, Ann Lazar, Igor Bondarenko,

Journal of Clinical Oncology

2012

272

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

Kathleen N. Moore, Amit M. Oza, Nicoletta Colombo,

Annals of Oncology

2021

265

Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies

Janice P. Dutcher, Paul de Souza, David F. McDermott,

Medical Oncology

2009

256

Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2–Dependent and Other Solid Tumors

Leena Gandhi, Rastislav Bahleda, Sara M. Tolaney,

Journal of Clinical Oncology

2013

197

Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features

Joaquim Bellmunt, Cezary Szczylik, Jay Feingold,

Annals of Oncology

2008

169

Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma

Birgit Geoerger, Mark W. Kieran, Stephan A. Grupp,

European Journal of Cancer

2011

140

Page 1